Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCold feet and a general feeling of being colder than usual have been reported by some people using Mounjaro (tirzepatide), though neither appears in the medicine's core list of common side effects. The current evidence suggests any cold sensation is most likely a downstream effect of rapid weight loss and reduced calorie intake rather than a direct action of the medicine on circulation. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber reviews your full health picture before it is dispensed. If your feet feel persistently cold, unusually numb, or noticeably pale, that is worth discussing with your clinical team rather than managing alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT trials, which enrolled thousands of adults and produced the evidence base behind Mounjaro's UK licence, reported a well-characterised side-effect profile dominated by gastrointestinal symptoms: nausea, diarrhoea, constipation and indigestion top the list, as the NHS tirzepatide medicines page sets out in detail. Cold feet do not appear in that profile, and that absence is not the same as saying it cannot happen; it means the trials did not find it occurring more often in the tirzepatide group than in people taking a placebo.
What the trials did confirm, unambiguously, is significant weight loss. In SURMOUNT-1, participants on the 15mg dose lost around 20–21% of their body weight on average over 72 weeks. That scale of change carries its own physiological consequences, and feeling colder is one of them. The cold sensation many people notice on Mounjaro almost certainly belongs in that category rather than in a separate, medicine-specific bucket.
This distinction matters practically. It shapes whether the right response is adjusting treatment or simply layering up and eating enough protein. You can read a fuller look at the cold-on-treatment experience on our cold on Mounjaro page.
Fat is not inert. It stores energy, yes, but it also acts as insulation and contributes to the metabolic rate that generates body heat. When body weight drops quickly, two things happen at once: resting metabolism slows slightly as the body adjusts to its new size, and the subcutaneous fat layer that buffers the skin from cold thins out. The result is that extremities, which have the highest surface-area-to-volume ratio in the body, lose heat faster than before.
There is also a circulatory element. Blood flow to the hands and feet is the first thing the body throttles when it prioritises warmth for core organs. In someone losing weight rapidly, peripheral circulation can be more variable than usual. None of this is dangerous in itself; it is the body doing exactly what bodies do during an energy deficit. The practical fix is often simple: eat regular warm meals, stay well hydrated, keep moving, and wear an extra pair of socks.
A common misconception worth gently addressing: some people worry that cold feet signal that Mounjaro is affecting the nerves or blood vessels of the legs directly. There is currently no clinical evidence to support that. The broader picture of foot-related symptoms on Mounjaro is worth reading if this is on your mind.
Most cases of cold feet on Mounjaro will settle once the body has adapted to a new, lower weight and calorie level. But some presentations call for proper medical assessment, and it is important to be clear about them.
Seek prompt advice from your GP or a clinician if the coldness is one-sided, if it comes with pain, pallor or a bluish tinge, if one foot feels noticeably colder than the other, or if you also have numbness or tingling that does not resolve. These features can point to peripheral arterial disease, Raynaud's phenomenon, or a neurological issue, none of which are caused by Mounjaro but all of which can be aggravated or masked by treatment-related changes.
If you have questions specific to your situation, our clinical support team is available seven days a week. And for anything that feels urgent, your GP or 111 is the right first call. The MHRA's Yellow Card scheme also allows patients to report any suspected side effect, which helps build the evidence base for all GLP-1 medicines over time.
People sometimes ask whether this cold feeling might indicate something neurological, such as nerve involvement. That question comes up enough that we have a page looking at whether Mounjaro has any connection to neurological symptoms, the short answer, based on current evidence, is reassuring, but the full picture is there if you want it.
For a broader overview of how tirzepatide works and what to expect, the tirzepatide overview pulls together the mechanism, the trial evidence and the eligibility criteria in one place. If you are weighing up whether to start treatment, our prescribers can also clarify whether starting Mounjaro requires you to notify your GP, and the free consultation with our prescribers is the right place to bring all of these questions together, a real clinician reviews every case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.